| Literature DB >> 22990654 |
D C Muller1, L Baglietto, J T Manning, C McLean, J L Hopper, D R English, G G Giles, G Severi.
Abstract
BACKGROUND: We aimed to assess whether 2D:4D measures are associated with breast cancer risk.Entities:
Mesh:
Year: 2012 PMID: 22990654 PMCID: PMC3493764 DOI: 10.1038/bjc.2012.418
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Characteristics of the 9044 women by breast cancer case status
|
|
|
| |
|---|---|---|---|
| Age at baseline (median, interquartile range) | 55 (48–62) | 53 (47–60) | 54 (47–61) |
| Right 2D : 4D (mean, standard deviation) | 0.961 (0.038) | 0.961 (0.037) | 0.961 (0.037) |
| Left 2D : 4D (mean, standard deviation) | 0.969 (0.037) | 0.966 (0.036) | 0.966 (0.036) |
| Δ | −0.008 (0.033) | −0.005 (0.034) | −0.005 (0.034) |
| Age at menopause (median, interquartile range) | 50 (48–53) | 50 (47–52) | 50 (47–52) |
|
| |||
| <12 | 99 (17) | 1378 (16) | 1477 (16) |
| 12 | 118 (20) | 1651 (20) | 1769 (20) |
| 13 | 150 (26) | 2295 (27) | 2445 (27) |
| ⩾14 | 204 (36) | 3128 (37) | 3332 (37) |
|
| |||
| Australia, New Zealand, United Kingdom | 491 (86) | 6303 (74) | 6794 (75) |
| Italy | 57 (10) | 1355 (16) | 1412 (16) |
| Greece | 25 (4) | 813 (10) | 838 (9) |
HRs and 95% CIs for 2D : 4D and breast cancer riska
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
| Overall | 1.12 | (1.02, 1.21) | 0.01 | 1.01 | (0.93, 1.10) | 0.85 | 0.90 | (0.83, 0.98) | 0.02 |
|
| 0.36 | 0.78 | 0.25 | ||||||
| Well differentiated | 0.98 | (0.81, 1.18) | 0.96 | (0.80, 1.16) | 0.98 | (0.81, 1.18) | |||
| Moderately differentiated | 1.10 | (0.98, 1.24) | 1.02 | (0.90, 1.16) | 0.93 | (0.82, 1.05) | |||
| Poorly or undifferentiated | 1.18 | (0.99, 1.40) | 0.95 | (0.79, 1.15) | 0.82 | (0.71, 0.94) | |||
|
| 0.62 | 0.78 | 0.86 | ||||||
| ER negative, PR negative | 1.21 | (1.00, 1.46) | 1.09 | (0.87, 1.36) | 0.89 | (0.75, 1.06) | |||
| ER positive, PR negative | 1.03 | (0.87, 1.23) | 0.96 | (0.81, 1.14) | 0.93 | (0.80, 1.09) | |||
| ER negative, PR positive | 1.25 | (0.82, 1.91) | 1.14 | (0.71, 1.83) | 0.78 | (0.52, 1.16) | |||
| ER positive, PR positive | 1.10 | (0.98, 1.24) | 0.98 | (0.87, 1.11) | 0.89 | (0.79, 1.00) | |||
Results estimated by Weibull survival models with age as the time axis, adjusted for country of birth. 2D : 4D measures were standardised so HRs reflect a 1-s.d. increase. P-values are from likelihood ratio tests of the overall coefficients, and Wald tests of heterogeneity between the HRs by tumour grade and ER and PR status.
Figure 1Time varying HR and 95% CI for a 1 s.d increase in 2D : 4D measures from flexible parametric time to event models, adjusted for country of birth.
Figure 2Predicted mean age at diagnosis and as a function of standardised 2D : 4D measures with 95% CI.
Hormone-related breast cancer risk factors and 2D : 4D measuresa
|
|
| |||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Left hand | −0.02 | (−0.05, 0.01) | 0.24 | −0.06 | (−0.22, 0.09) | 0.40 |
| Right hand | −0.03 | (−0.06, 0.01) | 0.12 | −0.25 | (−0.41, −0.10) | 0.001 |
| Δ | −0.01 | (−0.04, 0.03) | 0.64 | −0.16 | (−0.31, −0.01) | 0.04 |
Results estimated by linear regression models of age at menarche and age at menopause on standardised 2D : 4D measures, adjusting for country of birth. Coefficients represent the mean difference in years for a 1-s.d. increase in the 2D : 4D measure. P-values are from likelihood ratio tests of the regression coefficients.